Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study
- Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study
- The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide
- Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group
- The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7% for the control group
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing human pilot study that seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide. The study, which focused on Rybelsus(R), a commercially available semaglutide drug, involved seven healthy subjects, four of whom received the DehydraTECH GLP-1, with the other three receiving the control (https://nnw.fm/jtmfd ).
Of note was DehydraTECH GLP-1’s 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group. These results were achieved in the initial 100 minutes of taking the drugs, and at all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the control group. More so, even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline. In contrast, that of the control group was only reduced by 0.67%. This evidenced a nearly ten-fold improvement with DehydraTECH GLP-1.
When the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark, glucose levels spiked by 22.7% for the control group, while those in the DehydraTECH GLP-1 group only saw a 5.3% rise. Although this cannot be attributed to DehydraTECH GLP-1’s overall efficacy in achieving sustained blood glucose reduction, it is a plausible explanation for the difference and a pointer to the overall potential of the technology.
While there are still some additional steps to be taken, these positive results are welcome and point to the technology’s potential, specifically in diabetes treatment. In the DIAB-A22-1 animal study, Lexaria demonstrated at least three positive outcomes, which included weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The study also demonstrated an improvement in locomotor activity compared to untreated obese control rats, with no severe health concerns during dosing (https://nnw.fm/Cx0vd ).
With the results from Lexaria’s DehydraTECH GLP-1, the company is on track to replicate the positive results from its diabetes study. More importantly, it is on track to carve out a decent market share in an industry projected to bring between $150 billion and $200 billion a year (https://nnw.fm/wSixE ). By doing so, it will also ensure that GLP-1 drugs are more effective with reduced side effects while also being accessible to individuals living with diabetes. It also hopes it will improve the quality of life of people living with the condition by offering a less intrusive and less painful treatment alternative than what is currently in the market.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study
- The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide
- Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group
- The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7% for the control group
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing human pilot study that seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide. The study, which focused on Rybelsus(R), a commercially available semaglutide drug, involved seven healthy subjects, four of whom received the DehydraTECH GLP-1, with the other three receiving the control (https://nnw.fm/jtmfd ).
Of note was DehydraTECH GLP-1’s 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group. These results were achieved in the initial 100 minutes of taking the drugs, and at all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the control group. More so, even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline. In contrast, that of the control group was only reduced by 0.67%. This evidenced a nearly ten-fold improvement with DehydraTECH GLP-1.
When the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark, glucose levels spiked by 22.7% for the control group, while those in the DehydraTECH GLP-1 group only saw a 5.3% rise. Although this cannot be attributed to DehydraTECH GLP-1’s overall efficacy in achieving sustained blood glucose reduction, it is a plausible explanation for the difference and a pointer to the overall potential of the technology.
While there are still some additional steps to be taken, these positive results are welcome and point to the technology’s potential, specifically in diabetes treatment. In the DIAB-A22-1 animal study, Lexaria demonstrated at least three positive outcomes, which included weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The study also demonstrated an improvement in locomotor activity compared to untreated obese control rats, with no severe health concerns during dosing (https://nnw.fm/Cx0vd ).
With the results from Lexaria’s DehydraTECH GLP-1, the company is on track to replicate the positive results from its diabetes study. More importantly, it is on track to carve out a decent market share in an industry projected to bring between $150 billion and $200 billion a year (https://nnw.fm/wSixE ). By doing so, it will also ensure that GLP-1 drugs are more effective with reduced side effects while also being accessible to individuals living with diabetes. It also hopes it will improve the quality of life of people living with the condition by offering a less intrusive and less painful treatment alternative than what is currently in the market.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
